Compare EDSA & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDSA | CELZ |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 10.4M |
| IPO Year | N/A | N/A |
| Metric | EDSA | CELZ |
|---|---|---|
| Price | $1.76 | $2.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 29.0K | ★ 124.3K |
| Earning Date | 12-17-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.55 | $1.69 |
| 52 Week High | $4.49 | $6.90 |
| Indicator | EDSA | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 36.07 |
| Support Level | $1.67 | $2.08 |
| Resistance Level | $1.78 | $2.73 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 68.73 | 22.87 |
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.